Analysts think ALKS stock price could increase by 55%
Dec 06, 2025, 12:25 PM
-5.30%
What does ALKS do
Alkermes Plc is a biopharmaceutical company based in Dublin, focused on developing treatments for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, employing 2,100 people. Its key products include LYBALVI, ARISTADA, and VIVITROL, with ongoing development for neurological disorders and cancer.
18 analysts think ALKS stock price will increase by 55.46%. The current median analyst target is $45.90 compared to a current stock price of $29.52. The lowest analysts target is $30.30 and the highest analyst target is $60.90.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.